Navigation Links
Cequent Pharmaceuticals Founder to Present tkRNAi Technology at the,American Association of Cancer Research Annual Meeting in Los,Angeles

CAMBRIDGE, Mass., April 13, 2007 /PRNewswire/ -- Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, announced that its founder, Chiang Li, MD, will present a scientific poster on Cequent's proprietary TransKingdom RNA interference (tkRNAi(TM)) technology at the 2007 annual meeting of the American Association of Cancer Research (AACR). Co-inventor, Johannes Fruehauf, MD, PhD, of Beth Israel Deaconess Medical Center/Harvard Medical School, will also present at the centennial meeting, which will take place April 14 to 18, 2007, at the Los Angeles Convention Center.

The poster presentation, "Bacteria deliver RNA interference in vitro and in vivo for cancer therapy: tkRNAi," is scheduled for Tuesday, April 17, 2007, from 1 to 5 pm in the exhibit hall.

About tkRNAi(TM)- TransKingdom RNA Interference

RNA interference (RNAi) holds great promise for the development of novel therapies based on its high specificity and potency. One major difficulty impeding the wider development of RNAi-based therapies, however, is the need to deliver the molecules triggering RNAi (short interfering RNA) into the target cells and diseased tissues. Cequent's tkRNAi technology offers an elegant "Trojan horse" solution to the delivery problem; nonpathogenic bacteria are modified to produce and deposit mediators of RNA interference (short hairpin RNA) directly into the target cells. This method, which has been shown to induce gene silencing and therapeutic effects in multiple model systems, including live animals, forms the basis for Cequent's pipeline of clinical drug candidates.

About Cequent Pharmaceuticals, Inc.

An early-stage biopharmaceutical company, Cequent is pioneering the development of novel therapeutics to prevent and treat a wide range of human diseases - from inflammatory diseases to cancer - based on the company's proprietary technology, TransKingdom RNA interference (tkRNAi(TM)). The company's first products, now in pre-clinical development, are drug candidates targeting colon-cancer prevention and inflammatory bowel disease. Cequent designed its powerful tkRNAi technology to deactivate specific disease-causing genes safely and effectively, using non-pathogenic bacteria as an engine to produce and deliver RNAi directly into cells. It is based on ground-breaking scientific research originating at the Beth Israel Deaconess Medical Center/Harvard Medical School. A privately held company based in Cambridge, Massachusetts, Cequent was established in 2006 with seed funding from Ampersand Ventures, New England Partners, and Pappas Ventures. For more information, visit http://www.cequentpharma.com

About the AACR

The mission of the American Association for Cancer Research is to prevent and cure cancer. Founded in 1907, AACR is the world's oldest and largest professional organization dedicated to advancing cancer research. The membership includes more than 24,000 basic, translational, and clinical researchers; health care professionals; and cancer survivors and advocates in the United States and more than 70 other countries. AACR marshals the full spectrum of expertise from the cancer community to accelerate progress in the prevention, diagnosis and treatment of cancer through high-quality scientific and educational programs. It funds innovative, meritorious research grants. The AACR Annual Meeting attracts more than 17,000 participants who share the latest discoveries and developments in the field. For more information, visit http://www.aacr.org

CONTACT: Caroline Grossman of Cequent Pharmaceuticals, +1-781-771-5579, caroline.grossman@gmail.com

Web site: http://www.aacr.org/http://www.cequentpharma.com/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2017)... -- Centurion Medical Products, a leader in medical product innovation and global ... device for hospice patient care. ... Centurion Medical Products ... Patient pain management and emotional comfort are part of a hospice,s ... while preventing unneeded emergency department admission due to severe fecal impaction. ...
(Date:7/13/2017)... , July 13, 2017  New York City-based market ... pharmaceutical markets should be aware of.  From new products to ... are detailed in a recently completed study, Potential Pipeline ... 1.  Age-Driven Growth - ... have been aware of the impact the growing population and, ...
(Date:7/12/2017)... -- Eli Lilly and Company (NYSE: LLY ) has ... pending patent litigation in the U.S. District Court for the ... Cialis ® (tadalafil) unit dose patent. This patent was ... of the agreement, Cialis exclusivity is now expected to end ... unit dose patent for Cialis is valid and infringed by ...
Breaking Medicine Technology:
(Date:7/28/2017)... ... July 28, 2017 , ... Shamanic Teacher Anahata Ananda of ... is proud to announce the return of her increasingly popular “Shamanic Wisdom ... more about the mystical world of shamanism, nature wisdom, the medicine wheel, energy ...
(Date:7/27/2017)... ... July 27, 2017 , ... Dr. ... Board of Oral Implantology/Implant Dentistry (ABOI/ID). After successfully completing an extensive two-day examination ... of dental implants . Dr. Kimowitz and his partner Dr. Hal Kimowitz, ...
(Date:7/27/2017)... Longview, TX (PRWEB) , ... July 27, 2017 ... ... to receive a new set of teeth in a single office visit from ... convenient and comfortable treatment solutions to his East Texas patients, including Teeth-in-a-Day® ...
(Date:7/27/2017)... ... July 28, 2017 , ... DMG Productions is pleased to ... television series, American Famer, scheduled to broadcast fourth quarter 2017. American Farmer airs ... helping humanity face its toughest challenge: how to feed a rising population in ...
(Date:7/27/2017)... ... 27, 2017 , ... SSCI, a division of Albany Molecular ... worldwide, representing a milestone achievement. , As an industry-leading provider of ... have served as expert and fact witnesses to assist our clients to perform ...
Breaking Medicine News(10 mins):